产科护理共识第6号:围存活期分娩
该共识将围存活期分娩定义为孕20 0/7周至25 6/7周分娩,指出约0.5%的分娩发生在孕晚期前,这些极早产导致多数新生儿死亡和超过40%的婴儿死亡。除胎龄外,胎儿性别、体重、多胎、分娩地点、是否计划剖宫产或引产、产前皮质激素与硫酸镁使用、出生后重症监护的启动或撤停等因素与围存活期分娩的短期和长期结局相关。产前和产时管理选项包括短期宫缩抑制治疗为产前激素争取时间、抗生素用于胎膜早破后延长潜伏期或产时B族链球菌预防,以及因胎儿安危或胎位异常而分娩(包括剖宫产)。只要可能,计划干预的围存活期分娩应在具备母胎与新生儿专业能力及所需基础设施(包括重症监护病房)的中心进行。文件提供家庭咨询框架,以纳入知情患者偏好,支持根据个体情况和患者价值观决定拒绝或接受干预。
要点
- 围存活期分娩定义为孕20 0/7周至25 6/7周分娩。
- 约0.5%的分娩发生在孕晚期前,这些极早产导致多数新生儿死亡和超过40%的婴儿死亡。
- 除胎龄外,胎儿性别、体重、多胎、分娩地点、是否计划剖宫产或引产、产前皮质激素与硫酸镁使用、出生后重症监护的启动或撤停与围存活期分娩结局相关。
- 只要可能,计划干预的围存活期分娩应在具备母胎与新生儿专业能力及所需基础设施(包括重症监护病房)的中心进行。
- 产前和产时管理选项包括短期宫缩抑制治疗为产前激素争取时间、抗生素用于胎膜早破后延长潜伏期或产时B族链球菌预防,以及因胎儿安危或胎位异常而分娩(包括剖宫产)。
适用人群与场景
- 孕20 0/7周至25 6/7周分娩的围存活期分娩。
- 计划进行母体或新生儿干预的围存活期分娩,只要可能应在具备母胎与新生儿专业能力及所需基础设施(包括重症监护病房)的中心进行。
诊断标准与关键阈值
- 围存活期分娩定义为孕20 0/7周至25 6/7周分娩。
处置流程与药物剂量
- 短期宫缩抑制治疗用于早产临产,以争取产前激素给药时间。
- 抗生素用于胎膜早破后延长潜伏期,或用于产时B族链球菌预防。
- 因胎儿安危或胎位异常而分娩,包括剖宫产。
- 产前和产时管理选项因具体情况而异。
研究设计与关键结果
- 约0.5%的分娩发生在孕晚期前,这些极早产导致多数新生儿死亡和超过40%的婴儿死亡。
- 除胎龄外,不可改变因素(如胎儿性别、体重、多胎)、可能可改变的产前和产时因素(如分娩地点、是否计划剖宫产或引产、产前皮质激素与硫酸镁使用)及出生后管理(如出生后启动或暂缓、继续或撤停重症监护)与围存活期分娩的短期和长期结局相关。
证据类型、等级与局限
- 证据类型:产科护理共识(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 计划干预的围存活期分娩只要可能应在具备母胎与新生儿专业能力及所需基础设施(包括重症监护病房)的中心进行。
- 家庭咨询应纳入知情患者偏好,支持根据个体情况和患者价值观决定拒绝或接受干预及治疗。
指南或共识出处
- 产科护理共识第6号:围存活期分娩(Obstetric Care consensus No. 6: Periviable Birth),发表于Obstet Gynecol。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Approximately 0.5% of all births occur before the third trimester of pregnancy, and these very early deliveries result in the majority of neonatal deaths and more than 40% of infant deaths. A recent executive summary of proceedings from a joint workshop defined periviable birth as delivery occurring from 20 0/7 weeks to 25 6/7 weeks of gestation. When delivery is anticipated near the limit of viability, families and health care teams are faced with complex and ethically challenging decisions. Multiple factors have been found to be associated with short-term and long-term outcomes of periviable births in addition to gestational age at birth. These include, but are not limited to, nonmodifiable factors (eg, fetal sex, weight, plurality), potentially modifiable antepartum and intrapartum factors (eg, location of delivery, intent to intervene by cesarean delivery or induction for delivery, administration of antenatal corticosteroids and magnesium sulfate), and postnatal management (eg, starting or withholding and continuing or withdrawing intensive care after birth). Antepartum and intrapartum management options vary depending upon the specific circumstances but may include short-term tocolytic therapy for preterm labor to allow time for administration of antenatal steroids, antibiotics to prolong latency after preterm premature rupture of membranes or for intrapartum group B streptococci prophylaxis, and delivery, including cesarean delivery, for concern regarding fetal well-being or fetal malpresentation. Whenever possible, periviable births for which maternal or neonatal intervention is planned should occur in centers that offer expertise in maternal and neonatal care and the needed infrastructure, including intensive care units, to support such services. This document describes newborn outcomes after periviable birth, provides current evidence and recommendations regarding interventions in this setting, and provides an outline for family counseling with the goal of incorporating informed patient preferences. Its intent is to provide support and guidance regarding decisions, including declining and accepting interventions and therapies, based on individual circumstances and patient values.
参考来源
- Obstetric Care consensus No. 6: Periviable Birth. Obstet Gynecol. 2017. PMID: 28937572. doi:10.1097/AOG.0000000000002352
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。